FDA Brief

Warning letters Drugs

FDA warning letter to

Apothecary Health Solutions/Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop

MediumIssued Sep 20, 2021Posted Jan 18, 2022Office of Pharmaceutical Quality Operations, Division II

FDA cited Carie Boyd's Prescription Shop for compounded drugs that failed outsourcing-facility labeling and reporting rules.

What happened

FDA inspected the Irving, Texas facility from October 28 to November 12, 2019, and issued a Form FDA 483 (inspection observations) on November 12, 2019. The investigator found that compounded drugs failed section 503B conditions for outsourcing facilities: labels for estradiol and testosterone pellets lacked National Drug Code numbers and directions for use, the July 2019 product report omitted drugs, and an adverse-event report was sent after the 15-day deadline. FDA also cited the firm for unapproved new drugs and misbranded drugs.

What FDA found

  1. Labels for Estradiol Pellet 6mg and Testosterone Pellet 25mg did not include the National Drug Code number, and containers from which individual units are removed did not include directions for use.

    section 503B(a)(10)(A)(iii)(VIII) and section 503B(a)(10)(B)(iii) of the FDCA
  2. The July 2019 initial registration report did not identify all drug products compounded during the previous six-month period, including HCG Methylcobalamin B12 Injection and several testosterone and estradiol pellets.

    section 503B(b)(2) and section 301(ccc)(3) of the FDCA
  3. The firm became aware of a serious adverse drug experience on September 26, 2019, but FDA received the report on October 31, 2019, later than the required 15 calendar days.

    section 503B(b)(5) and section 301(ccc)(3) of the FDCA; 21 CFR 310.305(c)(1)
  4. The firm had no FDA-approved applications for its compounded drug products and marketed them, making them unapproved new drugs.

    sections 505(a) and 301(d) of the FDCA
  5. The compounded drugs are intended for conditions not amenable to self-diagnosis and treatment, so adequate directions for lay use cannot be written; labeling was therefore misbranded.

    section 502(f)(1) and section 301(a) of the FDCA

What FDA wants

Within 15 working days of receipt, notify FDA in writing of specific corrective steps, explanations, and supporting documentation, and state any reason and timeframe if full correction cannot be completed.

Who should pay attention

  • other 503B outsourcing facilities
  • clinics and pharmacies that use compounded hormone pellets or injections
  • quality teams handling labeling and adverse-event reports

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

    FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

    High risk
  2. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  3. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low